Shares of Aurobindo Pharma Ltd fell 3% after touching a day’s high of Rs 1,138.05 on 19th February, following the US FDA’s completion of a pre-approval inspection at its subsidiary, Eugia Steriles, which resulted in five procedural observations.

The US FDA inspected the firm’s subsidiary, Eugia Steriles, from 10th to 18th February, issuing five procedural observations, which the company plans to address within the prescribed time.

Aurobindo Pharma stated that it will update the stock exchanges if there are further developments regarding the inspection.

In December, the firm’s Telangana API facility received two observations from the US FDA after an inspection at Apitoria Pharma’s unit in Pashamylaram, Patancheru.

Earlier in September, the same Telangana facility had received 10 observations from the US health regulator.

In Q3FY25, Aurobindo Pharma’s net profit declined 9.7% YoY to Rs 845 crore, while revenue rose 8.5% YoY to Rs 7,978 crore, driven by strong sales in the US and emerging markets.

Despite revenue growth, operating performance remained weak, with EBITDA falling 1.5% YoY to Rs 1,627 crore in the third quarter.

At 1:55 PM, the shares of Aurobindo Pharma were trading 2.77% lower at Rs 1,131.10 on NSE.

Aurobindo Pharma Insights? Let the Analyst Guide You.

Unlock profitable opportunities every day! Unicorn Signals provides actionable intraday trading signals for stocks and futures. Don’t miss out – download Unicorn Signals and start winning now!